Clinical trials: Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
Macular Degeneration, Age-related Macular Degeneration
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.
- Conditions
- Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration
- Trial name
- MACULA (NCT01245387)
- Testing
- Pegaptanib
- Volunteers
- 1,001 people
- Sponsor
- Pfizer
Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye.
- Trial name
- NCT07744984
- Testing
- Home Optical Coherence Tomography (Home OCT)
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Rabin Medical Center
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
The purpose of this study is to obtain conjunctiva and tenon's capsule thickness measurements in vivo using spectral domain-optical coherence tomography (SD-OCT) in participants with nAMD/DME and age-matched healthy subjects.
- Trial name
- NCT06723288
- Where
- 20 sites in Spain
- Volunteers
- 736 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Neovascular (Wet) Age-Related Macular Degeneration
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.
- Trial name
- NCT07557121
- Testing
- AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Volunteers
- 35 people
- Sponsor
- AiViva BioPharma, Inc.
Age-related Macular Degeneration
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related…
- Trial name
- SUSHI (NCT03633084)
- Testing
- RBM-007 Injectable Solution
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Ribomic USA Inc
Age Related Macular Degeneration
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
Treatment of exudative age-related macular degeneration has been significantly improved by the advent of Lucentis™( which provides improved vision rather than simply stabilization) is common; however, monthly injections may be…
- Trial name
- MAP (NCT00605423)
- Testing
- Fluocinolone Acetonide/Medidur
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Macular Degeneration, Choroidal Neovascularization
Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.
- Trial name
- NCT03105609
- Testing
- Hyperspectral imaging
- Where
- Australia
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Age-Related Macular Degeneration
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing.
- Trial name
- NCT02291887
- Testing
- Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Associated Retinal Consultants, Michigan
Presence of Retinal Fluid, Changes in Macular Pigment Optical Density
Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes
Neovascular age-related macular degeneration (nAMD) is one of the main causes of irreversible vision loss in older people worldwide.
- Trial name
- NCT07074054
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Exudative Age-related Macular Degeneration
Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks.
- Trial name
- NCT01526070
- Testing
- Intravitreal injection of Aflibercept
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Stanford University
Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration
Evaluation of PAN-90806 Eye Drops in Healthy Subjects
The goal of this clinical trial is to learn about the safety, tolerability, and systemic pharmacokinetics of PAN-90806 eye drops in healthy adults.
- Trial name
- NCT07764965
- Testing
- PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Age-related Macular Degeneration
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
This study is conducted in 3 stages. Stage 1 is an open-label, dose-escalation assessment of the safety of AGN-150998 administered as a single intravitreal injection to patients with advanced exudative Age-related Macular…
- Trial name
- NCT01397409
- Testing
- AGN-150998, ranibizumab
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Allergan
Macular Edema, Macular Degeneration
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab…
- Trial name
- NCT02420132
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
- Trial name
- NCT07550504
- Testing
- SB11 PFS
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol…
- Trial name
- NCT02859766
- Testing
- Abicipar pegol
- Where
- 18 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergan
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration
SD-OCT Angiography
The objective of this study is to image retinal vascular alterations in patients with retinal disease using the AngioVue OCT-A system and understand the information these images provide.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- NCT02510885
- Testing
- AngioVue SD-OCT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University